Media headlines about LivaNova PLC (NASDAQ:LIVN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. LivaNova PLC earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.571451603195 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several brokerages have issued reports on LIVN. Berenberg Bank reissued a “buy” rating and set a $70.00 price objective on shares of LivaNova PLC in a research report on Friday, August 11th. Jefferies Group LLC lifted their target price on shares of LivaNova PLC from $76.00 to $80.00 and gave the company a “buy” rating in a report on Friday, September 15th. Needham & Company LLC raised shares of LivaNova PLC from a “hold” rating to a “buy” rating and set a $83.00 target price on the stock in a report on Friday, September 15th. Canaccord Genuity reaffirmed a “hold” rating and issued a $71.00 target price on shares of LivaNova PLC in a report on Wednesday, September 20th. Finally, BidaskClub downgraded shares of LivaNova PLC from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. LivaNova PLC currently has an average rating of “Hold” and a consensus target price of $71.50.

Shares of LivaNova PLC (NASDAQ LIVN) opened at 73.12 on Thursday. The stock has a 50 day moving average of $65.73 and a 200 day moving average of $59.50. The stock has a market cap of $3.57 billion, a P/E ratio of 130.57 and a beta of 0.59. LivaNova PLC has a one year low of $40.83 and a one year high of $73.40.

LivaNova PLC (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.19. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The business had revenue of $321.40 million during the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC’s quarterly revenue was up .1% compared to the same quarter last year. Equities analysts expect that LivaNova PLC will post $3.25 EPS for the current fiscal year.

In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $60.76, for a total value of $60,760.00. Following the completion of the transaction, the director now directly owns 58,296 shares in the company, valued at approximately $3,542,064.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $190,860 over the last quarter. 0.28% of the stock is owned by insiders.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect LivaNova PLC (LIVN) Stock Price” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-livanova-plc-livn-stock-price.html.

LivaNova PLC Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova PLC (NASDAQ:LIVN)

Receive News & Stock Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related stocks with our FREE daily email newsletter.